Cargando…

Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)

Today policy makers face the challenge to devise a policy framework that improves orphan medicinal product (OMP) development by creating incentives to deliver treatments where there are none and to authorize innovative and transformative treatments where treatments already exist. The European Expert...

Descripción completa

Detalles Bibliográficos
Autores principales: Aartsma-Rus, Annemieke, Dooms, Marc, Le Cam, Yann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717920/
https://www.ncbi.nlm.nih.gov/pubmed/34975469
http://dx.doi.org/10.3389/fphar.2021.744532
_version_ 1784624612997332992
author Aartsma-Rus, Annemieke
Dooms, Marc
Le Cam, Yann
author_facet Aartsma-Rus, Annemieke
Dooms, Marc
Le Cam, Yann
author_sort Aartsma-Rus, Annemieke
collection PubMed
description Today policy makers face the challenge to devise a policy framework that improves orphan medicinal product (OMP) development by creating incentives to deliver treatments where there are none and to authorize innovative and transformative treatments where treatments already exist. The European Expert Group on Orphan Drug Incentives (hereafter, OD Expert Group) came together in 2020 to develop policy proposals to facilitate EU policy makers to meet this challenge. The group brings together representatives of the broad rare disease community, including researchers, academia, patient representatives, members of the investor community, rare disease companies and trade associations. The group’s work builds on the recognition that only an ambitious policy agenda developed in a multi-stakeholder setting can bring about the quantum leap needed to address unmet needs of rare disease patients today. Along the OMP development path, the OD Expert Group has identified four main needs that a policy revision should address: 1) Need to improve the R&D ecosystem for basic research and company take-up of development. 2) Need to improve the system of financial incentives and rewards. 3) Need to improve the flexibility, predictability and speed of the regulatory pathway. 4) Need to improve the coherence and predictability of demand and pricing for OMPs. This article presents the results of the OD Expert Group work as a set of guiding principles that the revision of the policy framework should follow and a set of 14 policy proposals that address the main needs of OMP development in Europe today.
format Online
Article
Text
id pubmed-8717920
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87179202021-12-31 Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group) Aartsma-Rus, Annemieke Dooms, Marc Le Cam, Yann Front Pharmacol Pharmacology Today policy makers face the challenge to devise a policy framework that improves orphan medicinal product (OMP) development by creating incentives to deliver treatments where there are none and to authorize innovative and transformative treatments where treatments already exist. The European Expert Group on Orphan Drug Incentives (hereafter, OD Expert Group) came together in 2020 to develop policy proposals to facilitate EU policy makers to meet this challenge. The group brings together representatives of the broad rare disease community, including researchers, academia, patient representatives, members of the investor community, rare disease companies and trade associations. The group’s work builds on the recognition that only an ambitious policy agenda developed in a multi-stakeholder setting can bring about the quantum leap needed to address unmet needs of rare disease patients today. Along the OMP development path, the OD Expert Group has identified four main needs that a policy revision should address: 1) Need to improve the R&D ecosystem for basic research and company take-up of development. 2) Need to improve the system of financial incentives and rewards. 3) Need to improve the flexibility, predictability and speed of the regulatory pathway. 4) Need to improve the coherence and predictability of demand and pricing for OMPs. This article presents the results of the OD Expert Group work as a set of guiding principles that the revision of the policy framework should follow and a set of 14 policy proposals that address the main needs of OMP development in Europe today. Frontiers Media S.A. 2021-12-16 /pmc/articles/PMC8717920/ /pubmed/34975469 http://dx.doi.org/10.3389/fphar.2021.744532 Text en Copyright © 2021 Aartsma-Rus, Dooms and Le Cam. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Aartsma-Rus, Annemieke
Dooms, Marc
Le Cam, Yann
Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
title Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
title_full Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
title_fullStr Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
title_full_unstemmed Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
title_short Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
title_sort orphan medicine incentives: how to address the unmet needs of rare disease patients by optimizing the european orphan medicinal product landscape guiding principles and policy proposals by the european expert group for orphan drug incentives (od expert group)
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717920/
https://www.ncbi.nlm.nih.gov/pubmed/34975469
http://dx.doi.org/10.3389/fphar.2021.744532
work_keys_str_mv AT aartsmarusannemieke orphanmedicineincentiveshowtoaddresstheunmetneedsofrarediseasepatientsbyoptimizingtheeuropeanorphanmedicinalproductlandscapeguidingprinciplesandpolicyproposalsbytheeuropeanexpertgroupfororphandrugincentivesodexpertgroup
AT doomsmarc orphanmedicineincentiveshowtoaddresstheunmetneedsofrarediseasepatientsbyoptimizingtheeuropeanorphanmedicinalproductlandscapeguidingprinciplesandpolicyproposalsbytheeuropeanexpertgroupfororphandrugincentivesodexpertgroup
AT lecamyann orphanmedicineincentiveshowtoaddresstheunmetneedsofrarediseasepatientsbyoptimizingtheeuropeanorphanmedicinalproductlandscapeguidingprinciplesandpolicyproposalsbytheeuropeanexpertgroupfororphandrugincentivesodexpertgroup